Unknown

Dataset Information

Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes.


ABSTRACT:

Purpose

Metformin has been the first-line treatment for type 2 diabetes mellitus as monotherapy or concomitantly with other glucose-lowering therapies due to its efficacy, safety, and affordability. Recent studies on the cardioprotective and renoprotective benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have influenced guidelines on diabetes management to consider these newer agents as alternative first-line therapies. This paper explores the literature supporting the use of these newer medications alone as a first-line agent in place of metformin.

Methods

A review of citations from the most recent guidelines along with a literature search via PubMed was completed to review (1) what, historically, made

SUBMITTER: Andraos J 

PROVIDER: S-EPMC11196467 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature